Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028
Part B drugs will be negotiated for the first time in IPAY 2028. Policy changes, such as the OBBBA, exclude several high-cost products from negotiation. These policy decisions have major implications for how the Drug Price Negotiation Program targets high-spend drugs and achieves meaningful savings for the Medicare program.
Authors
- Sean D. Sullivan (ORCID: https://orcid.org/0000-0003-3052-6540)
- Emma M. Cousin (ORCID: https://orcid.org/0000-0003-1208-2173)
- Kristi Martin
- Ryan N. Hansen (ORCID: https://orcid.org/0000-0001-5571-6434)
- John Coster
Institutions
- University of Washington (US)
- Camber Collective (United States) (US)
- Centers for Medicare and Medicaid Services (US)
- London School of Economics and Political Science (GB)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.18553/jmcp.2025.25253
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00